SYNAGEVA BIOPHARMA CORP 4

Accession 0001209191-15-055580

CIK 0000911326operating

View on SEC.gov Company Profile

Filed

Jun 22, 8:00 PM ET

Accepted

Jun 23, 10:38 AM ET

Size

29.0 KB

Accession

0001209191-15-055580

Insider Transaction Report

Form 4

Period: 2015-06-22

SYNAGEVA BIOPHARMA CORPGEVA

DAVIS STEPHEN

Director

Transactions

Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−7,500→ 0 total
Exercise: $40.74Exp: 2022-06-27→ Common Stock (7,500 underlying)
Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−3,000→ 0 total
Exercise: $11.35Exp: 2020-09-22→ Common Stock (3,000 underlying)
Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−15,000→ 0 total
Exercise: $23.00Exp: 2021-12-20→ Common Stock (15,000 underlying)
Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−4,000→ 0 total
Exercise: $23.95Exp: 2017-06-27→ Common Stock (4,000 underlying)
Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−3,000→ 0 total
Exercise: $10.10Exp: 2019-07-21→ Common Stock (3,000 underlying)
Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−3,000→ 0 total
Exercise: $20.60Exp: 2018-06-26→ Common Stock (3,000 underlying)
Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−7,500→ 0 total
Exercise: $40.32Exp: 2023-06-06→ Common Stock (7,500 underlying)
Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−3,000→ 0 total
Exercise: $25.00Exp: 2017-08-14→ Common Stock (3,000 underlying)
Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−7,500→ 0 total
Exercise: $80.35Exp: 2024-06-04→ Common Stock (7,500 underlying)

Footnotes (9)

[F1]Pursuant to the Merger Agreement, these options, which vested 100% and became first exerciseable on July 21, 2010, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
[F2]Pursuant to the Merger Agreement, these options, which vested 100% and became first exerciseable on 9/22/2011, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
[F3]Pursuant to the Merger Agreement, these options, which vested 100% and became first exerciseable on June 26, 2009, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
[F4]Pursuant to the Merger Agreement, these options, which vest 25% on 12/02/2011 and 1/36 of the remainder of the shares vest and become exercisable monthly thereafter, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
[F5]Pursuant to the Merger Agreement, these options, which vest one-third every year over a three-year period and first become exercisable on the following schedule: 33.33% on June 27, 2008, 33.33% on June 27, 2009 and 33.33% on June 27, 2010, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
[F6]Pursuant to the Merger Agreement, these options, which vest 100% and first became exercisable on August 14, 2008, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
[F7]Pursuant to the Merger Agreement, these options, 1/12 of which vest on 07/06/2013 and 1/12 of which become exercisable monthly thereafter, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
[F8]Pursuant to the Merger Agreement, these options, 1/12 of which vest on 07/27/2012 and 1/12 of which become exercisable monthly thereafter, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
[F9]Pursuant to the Merger Agreement, these options, 1/12 of which vest on 07/04/2014 and 1/12 of which become exercisable monthly thereafter, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

SYNAGEVA BIOPHARMA CORP

CIK 0000911326

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0000911326

Filing Metadata

Form type: 4
Filed: Jun 22, 8:00 PM ET
Accepted: Jun 23, 10:38 AM ET
Size: 29.0 KB

View on SEC.gov